Pfizer’s EUA stays as FDA awaits report on Norway deaths — DOH | Inquirer News

Pfizer’s EUA stays as FDA awaits report on Norway deaths — DOH

/ 04:15 PM January 18, 2021

MANILA, Philippines — The emergency use authorization (EUA) for Pfizer’s Covid-19 vaccine will remain for now despite reports that some elderly people with underlying health conditions in Norway have died after getting inoculated with vaccine from the US-based pharmaceutical giant.

In an online press briefing on Monday, Health Undersecretary Maria Rosario Vergeire said the Food and Drug Administration (FDA) is awaiting Pfizer’s report regarding the deaths in Norway.

ADVERTISEMENT

“Ang sabi ng ating Food and Drug Administration, with this kind of occurrences, pinag-aaralan ‘yan and Pfizer has to submit to the Philippine FDA a report regarding this matter. Once we evaluate their report and base doon sa kanilang conclusion, that is the time that the FDA can decide on the EUA of Pfizer here in the country,” she said.

FEATURED STORIES

(The FDA said that with this kind of occurrence, this will have to be studied and Pfizer has to submit a report regarding this matter. Once we have evaluated their report and they have come up with a conclusion, that is time that the FDA can decide on the EUA of Pfizer in the country.)

“For now, hanggang wala pang malaking sufficient evidence to say na talagang ‘yan ay caused by the vaccine tayo po ay status quo pa rin sa ating binigay na EUA ng Pfizer,” she added.

(For now, as long as there is no sufficient evidence to say that the deaths are caused by the vaccine, the EUA of Pfizer remains under the status quo.)

Vergeire noted that Norwegian authorities have reported that those who died were critically ill and that the deaths could be merely coincidental to receiving the vaccines.

“But still they are not closing the issue. They would want to look into it further pero sa ngayon sinasabi nila (but for now, they are saying) they don’t think it is related,” she said.

The country’s FDA granted on January 14 a EUA for Pfizer, noting that interim data from phase 3 trials show that its Covid-19 vaccine has an efficacy of 95 percent in the study population and at least 92 percent among all racial groups.

EDV
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: coronavirus Philippines, COVID-19, Pfizer

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.